Join Growin Stock Community!

Daxor corporationDXR.US Overview

US StockHealthcare
(No presentation for DXR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DXR AI Insights

DXR Overall Performance

DXR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DXR Recent Performance

-2.02%

Daxor corporation

-3.61%

Avg of Sector

-2.16%

S&P500

DXR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DXR Key Information

DXR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DXR Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Price of DXR

DXR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DXR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.86
PE Ratio (TTM)
74.13
Forward PE
-
PS Ratio (TTM)
1042.30
PB Ratio
1.95
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
89.26%
Net Margin
311.68%
Revenue Growth (YoY)
801.80%
Profit Growth (YoY)
704.99%
3-Year Revenue Growth
72.59%
3-Year Profit Growth
66.18%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.86
PE Ratio (TTM)
74.13
Forward PE
-
PS Ratio (TTM)
1042.30
PB Ratio
1.95
Price-to-FCF
-
Gross Margin
89.26%
Net Margin
311.68%
Revenue Growth (YoY)
801.80%
Profit Growth (YoY)
704.99%
3-Year Revenue Growth
72.59%
3-Year Profit Growth
66.18%

  • When is DXR's latest earnings report released?

    The most recent financial report for Daxor corporation (DXR) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DXR's short-term business performance and financial health. For the latest updates on DXR's earnings releases, visit this page regularly.

  • What is the operating profit of DXR?

    According to the latest financial report, Daxor corporation (DXR) reported an Operating Profit of 2.21M with an Operating Margin of 317.17% this period, representing a growth of 623.1% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is DXR's revenue growth?

    In the latest financial report, Daxor corporation (DXR) announced revenue of 695.31K, with a Year-Over-Year growth rate of 743.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • Is DXR's EPS continuing to grow?

    According to the past four quarterly reports, Daxor corporation (DXR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.44. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DXR?

    Daxor corporation (DXR)'s Free Cash Flow (FCF) for the period is -502.05K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 86.75% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.